Novo Nordisk Shares Slide After Obesity Drug Misses Key Goal in Trial

Core Viewpoint - Shares of the Danish drugmaker fell sharply after the announcement that its CagriSema experimental obesity drug did not outperform Eli Lilly's Zepbound in a head-to-head clinical trial [1] Group 1 - The CagriSema drug is aimed at obesity treatment and was expected to compete with Eli Lilly's Zepbound [1] - The clinical trial results indicated that CagriSema failed to deliver better weight loss results compared to Zepbound [1] - The market reaction was negative, leading to a significant drop in the company's share price following the news [1]